N/A N=261 Incidence of Hepatic Hemangiomatosis in Patients With Cutaneous Hemangiomas
Hemangioma
Primary: Frequency of Hepatic Hemangiomas Identified on Abdominal Ultrasound — 24 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=357 Hemangioma Associated With High Rates of Morbidity
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
Phase 3 N=460 Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy
Infantile Hemangioma
Primary: Interim Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at Week 24 Compared to Baseline Based on the Intra-patient Blinded Centralized…
Phase 3 N=377 Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma
Hemangioma
Primary: The Primary Outcome Measure Was Any Response at 6 Months — 178; 173 Participants — p=<0.05
Phase 2 N=141 Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)
Infantile Hemangioma
Primary: Number of Participants With Partial Response of Hemangioma Volume as Measured by VAS (Visual Analog Scale) Within Each Treatment Arm and Compared With Untreated Controls…
Phase 4 N=34 The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma
Hemangioma
Primary: Number of Participants With Clinical Response From Baseline in Hemangioma Volume Measured by MRI or SONO — 14; 16 Participants
N/A N=27 Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
Port Wine Stain
Primary: Change From Baseline in a* and E at 8 Weeks — 1.27; 0.43; 4.08; 2.59 units on a scale
Phase 2 N=61 Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
Kaposiform Hemangioendotheliomas · Tufted Angioma · Capillary Venous Lymphatic Malformation
Primary: Overall Response by Radiologic Evaluation, Quality of Life Assessment, and Functional Impairment Score — 47; 7; 3 Participants
N/A N=22 Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment
Port-Wine Stain
Primary: Percent Change in Blanching of Port Wine Stain — 6; 5 percentage
Phase 2 N=55 Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
Obscure Gastrointestinal Bleeding · Angiodysplasia · Gastric Antral Vascular Ectasia
Primary: Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months — 20; 1 participants — p=0.00000013
Phase 2 N=10 Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Hereditary Hemorrhagic Telangiectasia
Primary: Change in Lesion Area of Treated Telangiectasia. — -6; -8 mm^2
Phase 2 N=275 OK432 (Picibanil) in the Treatment of Lymphatic Malformations
Lymphatic Malformations
Primary: Number of Participants With Clinical Success at 1 to 6 Months Post-Therapy as Assessed by Imaging — 57 Participants
Phase 2 N=20 Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study
Retinopathy of Prematurity
Primary: Regression of Retinopathy of Prematurity (ROP) in Premature Infants by Propranolol Therapy — 4; 8 cases
Phase 1 N=25 The CHILD Trial: Hypoplastic Left Heart Syndrome Study.
Hypoplastic Left Heart Syndrome
Primary: Number of Incidence of Treatment Related Major Adverse Cardiac Events — 1; 0; 6 Events
Phase 2 N=86 Study of PEG-Intron for Plexiform Neurofibromas
Plexiform Neurofibroma
Primary: Number of Participants With Imaging Response in Strata 1 and 2 — 0; 1; 1; 0 participants
N/A N=30 Healthy Eating for My Infant (HEMI)
Pediatric Obesity
Primary: Group Differences in Infant BMI — 5; 2; 9; 11 Participants
N/A N=102 Saphenous Vein Cannulation in Infants and Small Children
Saphenous Vein Cannulation
Primary: Percentage of Participants With First Attempt Success of Saphenous Vein Cannulation — 51.0; 90.2 percent of participants
N/A N=17 Combined Photodynamic and Pulsed Dye Laser Treatment of Port Wine Stains
Port Wine Stains
Primary: Blanching of Port Wine Stain Birthmark — 16 participants
N/A N=22 Clinical Evaluation of the Treatment of Spider Angioma
Spider Angioma
Primary: Physician's Global Assessment Scale for Improvement of Spider Angioma — 4.5 score on a scale
Phase 2 N=300 Infant TB Infection Prevention Study
Tuberculosis
Primary: Mycobacterium Tuberculosis (MTB) Infection — 10; 18 participants
Phase 3 N=431 Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial
Intraventricular Hemorrhage (IVH) · Bleeding in the Brain · Prematurity
Primary: IVH at 5 Postnatal Days — 25; 40 IVH
Phase 2 N=19 Sildenafil for the Treatment of Lymphatic Malformations
Lymphatic Malformations · Lymphatic Diseases
Primary: Change in Lesion Volume of the Test Medication as Evaluated by MRI Examination. — 5.89; -8.54; -0.642 percentage of volume
Phase 2 N=106 Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
Congenital Hyperinsulinism · Hyperinsulinism · Persistent Hyperinsulinemic Hypoglycemia of Infancy
Primary: The Accuracy of FDOPA PET to Identify Focal Forms of Hyperinsulinism — 40; 6; 3; 46 Participants
Phase 3 N=49 Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation
Heart Defects, Congenital
Primary: Number of Participants With Bleeding Events — 0; 2; 0; 0 participants
Phase 2 N=144 Pomalidomide for the Treatment of Bleeding in HHT
Telangiectasia, Hereditary Hemorrhagic
Primary: Change From Baseline Epistaxis Severity Score — -1; -1.1; -1.3; -1.2 units on a scale
Phase 4 N=20 INF108F in Infants With Food Protein Induced Proctocolitis
Infant Development · Gut Microbiome · Food Protein Induced Allergic Proctocolitis
Primary: Changes to Gut Microbiome Composition — 42.816; -12.413 Change in %B.infantis reads (Day 28-BL) — p=0.154
N/A N=340 Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Phase 2 N=6 High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia
Retinal Diseases · Telangiectasis
Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit
Phase 4 N=251 Survey of Inhibitors in Plasma-Product Exposed Toddlers
Hemophilia A
Primary: To Assess the Immunogenicity of Plasma Derived VWF/FVIII and rFVIII Concentrates by Determining the Frequency of Inhibitor Development in the First 50 EDs or in the…
Phase 3 N=1 CEUS Evaluation of Hypoxic Ischemic Injury
Hypoxic-Ischemic Encephalopathy · Brain Ischemia Hypoxia
Primary: Detection of Brain Perfusion Abnormalities Using Contrast-enhanced Ultrasound — 1; 0 Participants